Thursday 7 May, 2026
Introduction: Colorectal cancer (CRC) remains a leading cause of cancer incidence and mortality worldwide[1]. In Sweden, it ranks as the…
Read morePoster: Drug/Disease Modelling - Oncology
Using deconvolution to support the development of an abemaciclib parent-metabolite joint pharmacokinetic model
Thursday 7 May, 2026
Introduction: Abemaciclib is an orally administered drug targeting the cyclin-dependent kinase 4 and 6 (CDK4/6), responsible for tumour growth. It…
Read moreChallenges in Extending Semi-Mechanistic Neutropenia Models to Antibody-Drug Conjugate and Chemotherapy Combinations: Implications for G-CSF Dosing Optimisation
Thursday 7 May, 2026
Introduction/Objectives Chemotherapy-induced neutropenia remains a significant dose-limiting toxicity, and granulocyte colony-stimulating factor (G-CSF) prophylaxis represents a cornerstone of supportive care…
Read moreA MECHANISM-BASED PARSIMONIOUS CAR-T CELL POPULATION PK MODEL AND ITS VALIDATION VIA EXTENSION TO A POPULATION PK-TUMOR SIZE DYNAMICS MODEL: CASE STUDY WITH AXICABTAGENE CILOLEUCEL AND BREXUCABTAGENE AUTOLEUCEL
Thursday 7 May, 2026
Objectives: Chimeric antigen receptor (CAR)-T cell therapies display pharmacokinetics (PK) characterized by distribution, expansion, and elimination. These PK are often…
Read moreMODEL-INFORMED DRUG DEVELOPMENT TO SUPPORT DOSE SELECTION OF PASRITAMIG, A KLK2×CD3 BISPECIFIC ANTIBODY, IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Thursday 7 May, 2026
Objective To support the development of pasritamig, a KLK2×CD3 bispecific T‑cell engager, through model‑informed drug development (MIDD) methodologies, integrating population…
Read moreThe relationship between pre-operative ipilimumab and nivolumab pharmacokinetics and treatment outcome in locoregionally advanced urothelial cancer
Thursday 7 May, 2026
Objectives: In the NABUCCO trial, patients with locoregionally advanced urothelial cancer (UC) received three cycles of pre-operative ipilimumab and nivolumab…
Read moreMIXED-EFFECTS MODELING OF THE PLASMA KINETICS OF THE ANTI-CD8 PET TRACER [18F]-2C8v144 AND THE NON-BINDING CONTROL TRACER [18F]-2C8V145 ENABLES ESTIMATES OF THE TOTAL AMOUNT OF CD8 IN THE BODY AND THE FRACTION PRESENT IN BLOOD, AND THE EQUILIBRIUM DISSOCIATION CONSTANT (K_D) OF [18F]-2C8v144; AND PREDICTIONS OF TOTAL BODY RECEPTOR OCCUPANCY BY [18F]-2C8v144
Thursday 7 May, 2026
Introduction: The success of checkpoint-inhibition immunotherapy in cancer patients hinges on the presence of CD8+ (“cytotoxic”) T cells in tumors,…
Read moreExperimental and Virus-Specific Drivers of EC50 Variability in Antiviral Assays Evaluated Using Mathematical Modeling
Thursday 7 May, 2026
Abstract Background: The half-maximal effective concentrations (EC50) reported for specific antiviral agents often vary widely across in vitro studies. The…
Read moreMechanistic–Latent Class Modeling to Improve Response Classification in «Mouse Clinical Trials»
Thursday 7 May, 2026
Introduction: In oncology, high rates of therapeutic failure (particularly in late stages of clinical development) highlight the need to improve…
Read moreA PREDICTIVE MODELING FRAMEWORK TO RECONSTRUCT AND SIMULATE PFS
Thursday 7 May, 2026
Background: In advanced breast cancer, progression-free survival (PFS) is a primary registrational endpoint and a critical metric for early development…
Read more